Indivior (NASDAQ:INDV) Sets New 12-Month High – Here’s What Happened

Indivior PLC (NASDAQ:INDV) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $41.12 and last traded at $41.05, with a volume of 267098 shares. The stock had previously closed at $39.96.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on INDV. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Barclays began coverage on Indivior in a report on Thursday, June 18th. They set an “overweight” rating and a $46.00 price objective for the company. Finally, Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $40.29.

Indivior Trading Down 0.4%

The firm’s 50 day simple moving average is $36.85 and its two-hundred day simple moving average is $34.63. The firm has a market cap of $5.03 billion, a price-to-earnings ratio of 21.17 and a beta of 0.88.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The firm had revenue of $317.00 million during the quarter. As a group, equities research analysts anticipate that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares in the company, valued at approximately $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.74% of the company’s stock.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INDV. Rockefeller Capital Management L.P. grew its holdings in shares of Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after purchasing an additional 1,076 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares during the period. Virtu Financial LLC acquired a new position in Indivior in the fourth quarter valued at about $344,000. Invesco Ltd. raised its stake in Indivior by 274.6% in the fourth quarter. Invesco Ltd. now owns 286,689 shares of the company’s stock valued at $10,286,000 after purchasing an additional 210,150 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Indivior during the fourth quarter worth about $274,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.